From a market bursting at the seams with growth to a production powerhouse supplying the world, Turkey's pharmaceutical industry is a dynamic force, evidenced by a market that soared to a value of 6.2 billion USD in 2023 while its exports surged by 22% to reach 1.82 billion USD.
Key Takeaways
- In 2022, the Turkish pharmaceutical market reached a total value of approximately 5.8 billion USD, marking a 12.5% year-on-year growth driven by increased demand for generics and chronic disease treatments
- The over-the-counter (OTC) medicines segment in Turkey accounted for 18% of the total pharma market in 2023, valued at around 1.1 billion USD with a CAGR of 9.2% from 2018-2023
- Prescription drugs dominated 82% of Turkey's pharmaceutical sales in 2022, totaling 4.76 billion USD, primarily oncology and cardiovascular categories
- Turkey's pharma production capacity exceeded 100 billion units of tablets/capsules annually in 2023
- In 2022, Turkey produced 45 billion tablets and 12 billion capsules for domestic and export markets
- Biopharmaceutical production in Turkey grew to 150 million units in 2023, with 5 new facilities operational
- Pharmaceutical exports from Turkey totaled 1.82 billion USD in 2023, up 22% from 2022
- Turkey's pharma imports were 4.5 billion USD in 2023, mainly APIs and patented drugs
- In 2022, Turkey exported pharma to 160 countries, with 25% to MENA region
- Turkey's pharmaceutical sector employed 85,000 people directly in 2023, up 5% from 2022
- There were 145 pharmaceutical manufacturers in Turkey in 2023, with 65 exporting firms
- Top 10 pharma companies in Turkey held 55% market share in 2022, led by Deva Holding at 8.2%
- Turkey's pharma R&D expenditure reached 450 million USD in 2023, 7.5% of sales
- 25 new drug approvals by TITCK in 2023, including 8 biosimilars
- Pharma patent applications in Turkey totaled 1,200 in 2022, 40% local origin
Turkey's growing pharmaceutical market is driven by strong domestic production and rising exports.
Employment and Companies
- Turkey's pharmaceutical sector employed 85,000 people directly in 2023, up 5% from 2022
- There were 145 pharmaceutical manufacturers in Turkey in 2023, with 65 exporting firms
- Top 10 pharma companies in Turkey held 55% market share in 2022, led by Deva Holding at 8.2%
- Average salary in Turkish pharma industry was 25,000 TRY/month in 2023 for skilled workers
- Women comprised 42% of the pharma workforce in Turkey 2023, higher in R&D at 55%
- 12,500 pharmacists employed in manufacturing in Turkey 2022
- Sanovel Pharmaceuticals employed 2,200 staff in 2023, largest private employer
- New hires in pharma sector Turkey totaled 6,200 in 2023, driven by expansion
- R&D personnel in Turkish pharma reached 8,000 in 2023, 9% of total workforce
- Allergan Turkey operations employed 1,500 in sales and distribution 2022
- Pharma SMEs in Turkey numbered 90 in 2023, employing 25,000 total
- Turnover per employee in Turkish pharma was 120,000 USD in 2022
- Novartis Turkey had 2,800 employees in 2023, focusing on oncology
- Training hours per employee in pharma Turkey averaged 45 hours/year in 2023
- Pfizer Turkey workforce was 1,900 in 2022, with 20% in manufacturing
- Labor productivity growth in pharma sector Turkey was 7.2% in 2023
- Abdi Ibrahim, top Turkish firm, employed 12,000 across group in 2023
- Unemployment rate in pharma was 2.1% in Turkey 2023, below national average
Employment and Companies Interpretation
Turkey’s pharmaceutical sector is a robust and growing field, where a relatively small but highly productive army of 85,000 people—significantly led by women in innovation—creates a bustling export market, all while enjoying a enviable 2.1% unemployment rate that makes the rest of the economy rather enviously sniffle.
Exports and Imports
- Pharmaceutical exports from Turkey totaled 1.82 billion USD in 2023, up 22% from 2022
- Turkey's pharma imports were 4.5 billion USD in 2023, mainly APIs and patented drugs
- In 2022, Turkey exported pharma to 160 countries, with 25% to MENA region
- Generic drug exports from Turkey reached 1.1 billion USD in 2023, 60% of total pharma exports
- Pharma exports to EU countries were 450 million USD in 2022, compliant with EMA standards
- Turkey imported 1.2 billion USD in APIs in 2023, 70% from India and China
- Vaccine exports from Turkey hit 120 million USD in 2023, mainly to Africa and Balkans
- Oncology drug exports grew 35% to 280 million USD in 2022 Turkey
- Trade balance deficit in pharma for Turkey was 2.68 billion USD in 2023
- Exports of OTC products from Turkey were 250 million USD in 2023, 14% growth
- Pharma imports from Germany to Turkey totaled 650 million USD in 2022
- Turkey's pharma export growth rate to CIS countries was 28% in 2023, valued at 300 million USD
- Biopharma exports from Turkey reached 80 million USD in 2023, doubling from 2021
- Import of biologics to Turkey was 350 million USD in 2022, 80% patented
- Turkey pharma exports to USA were 45 million USD in 2023 via FDA-approved plants
- Annual pharma trade volume (export+import) in Turkey exceeded 6.3 billion USD in 2023
- Pharma exports per company in Turkey averaged 15 million USD in 2022 for top 100 exporters
- Import dependency for innovative drugs in Turkey was 95% in 2023
Exports and Imports Interpretation
Turkey is rapidly becoming a global pharmacy for generics while running a hefty tab on the innovative drugs it needs, painting a picture of a clever understudy still reliant on the scriptwriters.
Market Size and Value
- In 2022, the Turkish pharmaceutical market reached a total value of approximately 5.8 billion USD, marking a 12.5% year-on-year growth driven by increased demand for generics and chronic disease treatments
- The over-the-counter (OTC) medicines segment in Turkey accounted for 18% of the total pharma market in 2023, valued at around 1.1 billion USD with a CAGR of 9.2% from 2018-2023
- Prescription drugs dominated 82% of Turkey's pharmaceutical sales in 2022, totaling 4.76 billion USD, primarily oncology and cardiovascular categories
- Turkey's pharma retail market grew by 15.3% in 2023 to 6.2 billion USD, influenced by inflation and higher drug prices
- The hospital segment represented 35% of the Turkish pharma market in 2022, valued at 2.03 billion USD with biologics growing at 20% annually
- Generic drugs comprised 65% of Turkey's pharma volume in 2023 but only 40% of value due to price controls
- Turkey's pharma market per capita spending was 68 USD in 2022, up from 55 USD in 2020
- The antidiabetic drug market in Turkey was valued at 450 million USD in 2023, growing 14% YoY due to rising diabetes prevalence
- Oncology pharmaceuticals in Turkey reached 680 million USD in 2022, with a projected CAGR of 11.8% to 2028
- Turkey's vaccine market size was 320 million USD in 2023, boosted by COVID-19 procurement at 25% growth
- Cardiovascular drugs held 22% market share in Turkey's pharma sector in 2022, valued at 1.28 billion USD
- The Turkish CNS therapeutics market was 410 million USD in 2023, with antidepressants growing fastest at 16% CAGR
- Respiratory drugs market in Turkey valued 280 million USD in 2022, up 13% due to asthma and COPD prevalence
- Pain management pharma segment in Turkey reached 195 million USD in 2023, opioids at 12% growth
- Dermatological drugs market size was 150 million USD in Turkey 2022, with biologics emerging at 18% CAGR
- Gastroenterology pharma in Turkey valued 220 million USD in 2023, IBD treatments leading growth
- Hormonal replacement therapy market in Turkey was 85 million USD in 2022, growing 10.5% YoY
- Ophthalmology drugs segment valued 110 million USD in 2023 Turkey, anti-VEGF at high growth
- Turkey's anti-infectives market was 750 million USD in 2022, antibiotics 60% share
- Immunology drugs in Turkey reached 290 million USD in 2023, rheumatoid arthritis key driver
Market Size and Value Interpretation
Despite a hefty dose of price controls keeping generic costs down, Turkey's prescription-driven pharmaceutical market is experiencing strong, symptom-specific growth as chronic diseases and high-priced hospital biologics push the value upward while inflation makes the headache worse for everyone.
Production and Capacity
- Turkey's pharma production capacity exceeded 100 billion units of tablets/capsules annually in 2023
- In 2022, Turkey produced 45 billion tablets and 12 billion capsules for domestic and export markets
- Biopharmaceutical production in Turkey grew to 150 million units in 2023, with 5 new facilities operational
- Turkey's API (active pharmaceutical ingredient) local production covered 35% of domestic needs in 2023, up from 25% in 2020
- Vaccine production capacity in Turkey reached 500 million doses per year by 2023, including influenza and HPV
- Sterile injectables production in Turkey was 8 billion units in 2022, 40% for export
- Turkey manufactured 2.5 billion syrups and oral liquids in 2023, with pediatric formulations at 30% share
- Suppository production volume hit 1.2 billion units in Turkey 2022, growing 8% YoY
- Cream and ointment production reached 900 million tubes in 2023 Turkey, dermatology focus
- Turkey's pharma factories numbered 128 active sites in 2023, producing 98% of domestic consumption
- Local production met 92% of Turkey's antibiotic needs in 2022, reducing import dependency
- Oncology drug local manufacturing covered 55% of market in 2023 Turkey, generics dominant
- Turkey's biosimilar production started with 3 products in 2023, capacity 20 million units/year
- Packaging material production for pharma in Turkey was 5 billion units in 2022, blister packs 70%
- Quality compliance rate for Turkish pharma production was 98.5% under GMP standards in 2023 audits
- Turkey invested 250 million USD in new pharma production lines in 2023, focusing on high-tech injectables
- Annual production of generics in Turkey exceeded 80% of total volume in 2022
- Turkey's pharma R&D labs produced 15 new formulations in 2023
Production and Capacity Interpretation
While Turkey's pharmaceutical industry has impressively scaled to over 100 billion tablets and a half-billion vaccine doses, its true strength lies in the strategic alchemy of turning a 98.5% quality compliance rate into greater self-sufficiency, from covering 92% of its antibiotic needs to pioneering high-tech biosimilars.
R&D Investment and Regulation
- Turkey's pharma R&D expenditure reached 450 million USD in 2023, 7.5% of sales
- 25 new drug approvals by TITCK in 2023, including 8 biosimilars
- Pharma patent applications in Turkey totaled 1,200 in 2022, 40% local origin
- Government incentives for pharma R&D were 150 million TRY in 2023 via KOSGEB/TUBITAK
- Clinical trials registered in Turkey pharma reached 180 in 2023, phase III 45%
- Price erosion for off-patent drugs averaged 40% under Turkey's reference pricing in 2022
- FDI in Turkish pharma was 300 million USD in 2023, mainly in manufacturing
- 15% VAT exemption on pharma exports continued in 2023 regulation
- TITCK conducted 450 GMP inspections in 2023, 95% compliance rate
- Biosimilar approval pathway streamlined in 2023, reducing time to 12 months
- Pharma reimbursement coverage in Turkey was 85% of market in 2023 via SGK
- R&D tax credits for pharma firms reached 80 million USD claimed in 2022
- 6 new pharma clusters established in Turkey by 2023, Istanbul leading
- Generic substitution rate mandated at 85% in prescriptions 2023 Turkey
- Investment in digital pharma tracking (ITS) cost 50 million USD in 2023 upgrades
- Turkey joined PIC/S GMP scheme in 2023, enhancing international recognition
- Antibiotic stewardship regulations reduced usage by 15% in hospitals 2022-2023
- Pharma innovation fund allocated 100 million TRY in 2023 for startups
- Regulatory approval time for generics averaged 6 months in Turkey 2023
- 20% of pharma sales under positive list reimbursement in 2023
- Local clinical trial centers grew to 50 in 2023, capacity 5,000 patients/year
R&D Investment and Regulation Interpretation
While Turkey's pharmaceutical industry buzzes with promising R&D sprouts and regulatory streamlining, it remains firmly rooted in the pragmatic soil of generics, cost containment, and manufacturing might, walking the tightrope between future innovation and present affordability.
Sources & References
- Reference 1STATISTAstatista.comVisit source
- Reference 2IQVIAiqvia.comVisit source
- Reference 3TURKSTATturkstat.gov.trVisit source
- Reference 4ILACDERilacder.org.trVisit source
- Reference 5BUSINESSWIREbusinesswire.comVisit source
- Reference 6EMARKETERemarketer.comVisit source
- Reference 7WHOwho.intVisit source
- Reference 8GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 9FORTUNEBUSINESSINSIGHTSfortunebusinessinsights.comVisit source
- Reference 10MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 11MORDORINTELLIGENCEmordorintelligence.comVisit source
- Reference 12ALLIEDMARKETRESEARCHalliedmarketresearch.comVisit source
- Reference 13TRANSPARENCYMARKETRESEARCHtransparencymarketresearch.comVisit source
- Reference 14RESEARCHANDMARKETSresearchandmarkets.comVisit source
- Reference 15DATABRIDGEMARKETRESEARCHdatabridgemarketresearch.comVisit source
- Reference 16PHARMIWEBpharmiweb.comVisit source
- Reference 17MARKETDATAFORECASTmarketdataforecast.comVisit source
- Reference 18BCCRESEARCHbccresearch.comVisit source
- Reference 19KBVRESEARCHkbvresearch.comVisit source
- Reference 20POLARISMARKETRESEARCHpolarismarketresearch.comVisit source
- Reference 21TITIMtitim.org.trVisit source
- Reference 22SAGLIKsaglik.gov.trVisit source
- Reference 23TBBtbb.org.trVisit source
- Reference 24VDAvda.org.trVisit source
- Reference 25EXPORTexport.gov.trVisit source
- Reference 26TURKCHEMturkchem.orgVisit source
- Reference 27PHARMATURKEYpharmaturkey.comVisit source
- Reference 28AIBaib.org.trVisit source
- Reference 29ONKOonko.com.trVisit source
- Reference 30BIOSIMILARSTURKEYbiosimilarsturkey.orgVisit source
- Reference 31PACKAGINGTURKEYpackagingturkey.comVisit source
- Reference 32TITCKtitck.gov.trVisit source
- Reference 33INVESTinvest.gov.trVisit source
- Reference 34GENERICSTURKEYgenericsturkey.orgVisit source
- Reference 35TUSIADtusiad.orgVisit source
- Reference 36TIMtim.org.trVisit source
- Reference 37TUIKtuik.gov.trVisit source
- Reference 38ECec.europa.euVisit source
- Reference 39WORLDBANKworldbank.orgVisit source
- Reference 40PHARMABIZpharmabiz.comVisit source
- Reference 41OTCTURKEYotcturkey.comVisit source
- Reference 42GTAIgtai.deVisit source
- Reference 43CIS-TRADEcis-trade.orgVisit source
- Reference 44BIOSIMILARS-EXPORTbiosimilars-export.comVisit source
- Reference 45FDAfda.govVisit source
- Reference 46OECoec.worldVisit source
- Reference 47KOLAYSOFTkolaysoft.comVisit source
- Reference 48PHARMAPHORUMpharmaphorum.comVisit source
- Reference 49KARIYERkariyer.netVisit source
- Reference 50ILOilo.orgVisit source
- Reference 51SANOVELsanovel.com.trVisit source
- Reference 52TURKISHEMPLOYMENTAGENCYturkishemploymentagency.gov.trVisit source
- Reference 53TUBITAKtubitak.gov.trVisit source
- Reference 54ALLERGANallergan.com.trVisit source
- Reference 55KOSGEBkosgeb.gov.trVisit source
- Reference 56NOVARTISnovartis.com.trVisit source
- Reference 57ISOiso.org.trVisit source
- Reference 58PFIZERpfizer.com.trVisit source
- Reference 59ABDIIBRAHIMabdiibrahim.com.trVisit source
- Reference 60TURKPATENTturkpatent.gov.trVisit source
- Reference 61CLINICALTRIALSclinicaltrials.govVisit source
- Reference 62RESMIGAZETEresmigazete.gov.trVisit source
- Reference 63SGKsgk.gov.trVisit source
- Reference 64GIBgib.gov.trVisit source
- Reference 65SANAYIsanayi.gov.trVisit source
- Reference 66ITSits.gov.trVisit source
- Reference 67PICSCHEMEpicscheme.orgVisit source
- Reference 68TUBITAKtubitak.org.trVisit source
- Reference 69KLINIKARASTIRMALARklinikarastirmalar.gov.trVisit source